María-Belen Vidriales

10PUBLICATIONS
76CO-AUTHORS
Medical infection agents (incl. prions)Transplantation immunologyRespiratory diseasesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 31, 2026
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

|Sep 01, 2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.

Ana Alfonso-Pierola, David Martinez-Cuadrón, Rebeca Rodríguez-Veiga

|Dec 17, 2024
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.

Susana Vives, David Quintela, Mireia Morgades

|Jun 10, 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.

David Martínez-Cuadrón, Josefina Serrano, José Mariz

|Jul 21, 2021
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.

Hardikkumar Jetani, Almudena Navarro-Bailón, Marius Maucher

|Feb 02, 2021
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.

Bruno Paiva, María-Belen Vidriales, Amparo Sempere

Pageof 2

Frequent Collaborators

5 joint publications

David Martínez-Cuadrón

5 joint publications

Teresa Del Bernal Del Castillo

5 joint publications

Pau Montesinos

4 joint publications

Manuel Pérez-Encinas